SCHEMBL2087034

SCHEMBL2087034

C1=NC2(CC1)CCCCC2

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3463426 0.97
SCHEMBL31042646 0.88
SCHEMBL11811204 0.61
SCHEMBL2223430 0.58
SCHEMBL352623 0.56
SCHEMBL2868390 0.56
SCHEMBL2049131 0.54
SCHEMBL69662 0.52
SCHEMBL11773655 0.52
SCHEMBL380648 0.51

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-109745309-B Mitsuma as antiviral agent 香港浸会大学 2022-01-28 CN disclosed
US-10323012-B2 Miliusanes as antiviral agents HONG KONG BAPTIST UNIVERSITY (HK) 2019-06-18 US disclosed
US-20180065946-A1 Miliusanes As Antiviral Agents HONG KONG BAPTIST UNIVERSITY (HK) 2018-03-08 US disclosed
US-20180065946-A1 Miliusanes As Antiviral Agents HONG KONG BAPTIST UNIVERSITY (HK) 2018-03-08 US disclosed
US-9822071-B2 Anticancer miliusane lactams HONG KONG BAPTIST UNIVERSITY (HK) 2017-11-21 US disclosed
US-9822071-B2 Anticancer miliusane lactams HONG KONG BAPTIST UNIVERSITY (HK) 2017-11-21 US disclosed
US-9822071-B2 Anticancer miliusane lactams HONG KONG BAPTIST UNIVERSITY (HK) 2017-11-21 US disclosed
US-20170267635-A1 Anticancer Miliusane Lactams HONG KONG BAPTIST UNIVERSITY (HK) 2017-09-21 US disclosed
US-20170267635-A1 Anticancer Miliusane Lactams HONG KONG BAPTIST UNIVERSITY (HK) 2017-09-21 US disclosed
US-9695141-B2 Anticancer miliusane derivatives HONG KONG BAPTIST UNIVERSITY (HK) 2017-07-04 US disclosed
US-7754708-B2 N-aryl azaspiroalkene and azaspiroalkane compounds and methods of preparation and use thereof TARGACEPT, INC. (US) 2010-07-13 US disclosed
US-20100093788-A1 HETEROCYCLIC BENZIMIDAZOLES AS TRPM8 MODULATORS JANSSEN PHARMACEUTICA N.V. (BE) 2010-04-15 US disclosed
US-20080242689-A1 Analgesics, central nervous system disorders, obesity, side effect reduction BHATTI BALWINDER 2008-10-02 US disclosed
US-20080161331-A1 Compounds Comprising an Oxazoline or Thiazoline Moiety, Processes for Making Them, and Their Uses UCB PHARMA, S.A. (BE) 2008-07-03 US disclosed
US-7384929-B2 N-aryl azaspiroalkene and azaspiroalkane compounds and methods of preparation and use thereof TARGACEPT, INC. (US) 2008-06-10 US disclosed
EP-1866294-A1 COMPOUNDS COMPRISING AN OXAZOLINE OR THIAZOLINE MOIETY, PROCESSES FOR MAKING THEM, AND THEIR USES UCB Pharma, S.A. (BE) 2007-12-19 EP disclosed
EP-1802601-A1 AZASPIROALKENE AND AZAPIROALKANE COMPOUNDS WITH NICOTINIC CHOLINERGIC RECEPTOR ACTIVITY Targacept, Inc. (US) 2007-07-04 EP disclosed
WO-2006103057-A1 COMPOUNDS COMPRISING AN OXAZOLINE OR THIAZOLINE MOIETY, PROCESSES FOR MAKING THEM, AND THEIR USES UCB PHARMA, S.A. (BE) 2006-10-05 WO disclosed
US-20060074067-A1 N-aryl azaspiroalkene and azaspiroalkane compounds and methods of preparation and use thereof BHATTI BALWINDER 2006-04-06 US disclosed
WO-2006034089-A1 AZASPIROALKENE AND AZASPIROALKANE COMPOUNDS WITH NICOTINIC CHOLINERGIC RECEPTOR ACTIVITY TARGACEPT, INC. (US) 2006-03-30 WO disclosed